Conformations and interactions comparison between R- and S-methadone in wild type CYP2B6, 2D6 and 3A4
-
Nik Nur Syazana Bt Nik Mohamed Kamal
Abstract
Methadone is a morphine-substitute drug in methadone maintenance treatment (MMT) program to treat patients with opioid dependency. However, the methadone clinical effects are depending on the methadone metabolism rates that vary among the patients with genetic polymorphism of cytochrome P450s (CYPs). Our previous study showed methadone has different binding affinity due to the polymorphisms in CYP2B6, CYP2D6 and CYP3A4 that could contribute to the methadone metabolism rate. In this work, the conformation and interactions of R- and S-methadone in wild type CYP2B6, CYP2D6 and CYP3A4 were further studied in order to understand behaviour of R- and S-methadone at the CYP binding site. Clustering analysis showed that the conformation of R- and S-methadone in CYP2B6 are most stable, thus could lead to a higher efficiency of methadone metabolism. The conformation fluctuation of methadone in CYP2D6 could due to relatively smaller binding pocket compared with CYP2B6 and CYP3A4. The binding sites volumes of the studied CYPs were also found to be increased upon the binding with methadone. Therefore, this might contributed to the interactions of both R- and S-methadone in CYPs were mainly by hydrophobic contacts, van der Waals and electrostatic interactions. In the future, should an inhibitor for CYP is to be designed to prolong the prolonged opioid effect, the inhibitor should cater for single CYP isozyme as this study observed the behavioural differences of methadone in CYP isozymes.
Graphical Abstract:
Acknowledgements
This work was supported by Fundamental Research Grant Scheme (FRGS;203/CIPPM/6711680) from Malaysia Ministry of Education. Appreciation also extended to Universiti Sains Malaysia Postgraduate Research Scholarship for NNSBNM Kamal.
References
[1] Bowen S, Somohano VC, Rutkie RE, Manuel JA, Rehder KL. Mindfulness-based relapse prevention for methadone maintenance: A feasibility trial. J Altern Complement Med. 2017;23:541–4.10.1089/acm.2016.0417Suche in Google Scholar PubMed
[2] Chhabra S, Bull J. Methadone. Am J Hosp Palliat Care. 2008;25:146–50.10.1177/1049909107312597Suche in Google Scholar PubMed
[3] El Hage C, Ghabrash MF, Dubreucq S, Brissette S, Lesperance F, Lesperance P, et al. A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder. Int Clin Psychopharmacol. 2018;33:268–73.10.1097/YIC.0000000000000223Suche in Google Scholar PubMed
[4] Fishman SM, Wilsey B, Mahajan G, Molina P. Methadone reincarnated: novel clinical applications with related concerns. Pain Med. 2002;3:339–48.10.1046/j.1526-4637.2002.02047.xSuche in Google Scholar PubMed
[5] Maremmani AG, Pacini M, Maremmani I. What we have learned from the methadone maintenance treatment of dual disorder heroin use disorder patients. Int J Environ Res Public Health. 2019;16:447.10.3390/ijerph16030447Suche in Google Scholar PubMed PubMed Central
[6] Gadel S, Crafford A, Regina K, Kharasch ED. Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6. Drug Metab Dispos. 2013;41:709–13.10.1124/dmd.112.050625Suche in Google Scholar PubMed PubMed Central
[7] Kharasch ED, Hoffer C, Whittington D, Walker A, Bedynek PS. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. Anesthesiology. 2009;110:660–72.10.1097/ALN.0b013e3181986a9aSuche in Google Scholar PubMed PubMed Central
[8] Peng S, Jiang H, Du J, Lin S, Pan S, Yu S, et al. Methadone dosage and plasma levels, SNPs of OPRM1 gene and age of first grug use were associated with outcomes of methadone maintenance treatment. Front Genet. 2018;9:450.10.3389/fgene.2018.00450Suche in Google Scholar PubMed PubMed Central
[9] Russolillo A, Moniruzzaman A, Somers JM. Methadone maintenance treatment and mortality in people with criminal convictions: A population-based retrospective cohort study from Canada. PLoS Med. 2018;15:e1002625.10.1371/journal.pmed.1002625Suche in Google Scholar PubMed PubMed Central
[10] Fonseca F, de la Torre R, Diaz L, Pastor A, Cuyas E, Pizarro N, et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One. 2011;6:e19527.10.1371/journal.pone.0019527Suche in Google Scholar PubMed PubMed Central
[11] Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004;76:250–69.10.1016/j.clpt.2004.05.003Suche in Google Scholar PubMed
[12] Levran O, Peles E, Hamon S, Randesi M, Adelson M, Kreek MJ. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol. 2013;18:709–16.10.1111/j.1369-1600.2011.00349.xSuche in Google Scholar PubMed PubMed Central
[13] Volpe DA, Xu Y, Sahajwalla CG, Younis IR, Patel V. Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018;107:2983–91.10.1016/j.xphs.2018.08.025Suche in Google Scholar PubMed
[14] Kharasch ED. Current concepts in methadone metabolism and transport. Clin Pharmacol Drug Dev. 2017;6:125–34.10.1002/cpdd.326Suche in Google Scholar PubMed PubMed Central
[15] Kamal NN, Lim TS, Tye GJ, Ismail R, Choong YS. The effect of CYP2B6, CYP2D6 and CYP3A4 alleles on methadone bonding: A molecular docking study. J Chem. 2013;2013:249642.10.1155/2013/249642Suche in Google Scholar
[16] Shiran MR, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT, et al. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol. 2009;67:29–37.10.1111/j.1365-2125.2008.03312.xSuche in Google Scholar PubMed PubMed Central
[17] Fonseca F, Torrens M. Pharmacogenetics of methadone response. Mol Diagn Ther. 2018;22:57–78.10.1007/s40291-017-0311-ySuche in Google Scholar PubMed
[18] Maremmani I. The Principles and Practice of Methadone Treatment. Pacini Editore Medicina & AU–CNS. Pisa. 2009.Suche in Google Scholar
[19] Karch SB, Stephens BG. Toxicology and pathology of deaths related to methadone: retrospective review. West J Med. 2000;172:11–14.10.1136/ewjm.172.1.11Suche in Google Scholar PubMed PubMed Central
[20] Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F. Steady-State Pharmacokinetics of (R)- and (S)-Methadone in Methadone Maintenance Patients. Clin Pharmacol. 2000;50:427–40.10.1046/j.1365-2125.2000.00272.xSuche in Google Scholar PubMed PubMed Central
[21] Kharasch ED, Regina KJ, Blood J, Friedel C. Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism. Anesthesiology. 2016;123:1142–53.10.1097/SA.0000000000000227Suche in Google Scholar
[22] Ahmad T, Valentovic MA, Rankin GO. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics. Biochem Pharmacol. 2018;153:196–204.10.1016/j.bcp.2018.02.020Suche in Google Scholar PubMed
[23] Peng PW, Tumber PS, Gourlay D. Perioperative Pain Management of Patients on Methadone Therapy. Reg Anesthesia Pain. 2005;52:513–23.Suche in Google Scholar
[24] Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993;234:779–815.10.1006/jmbi.1993.1626Suche in Google Scholar PubMed
[25] Case DA, Darden TA, Cheatham IT, Simmerling CL, Wang J, Duke RE, et al. AMBER11. San Franscisco: University of California, 2010.Suche in Google Scholar
[26] Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, et al. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem. 2003;24:1999–2012.10.1002/jcc.10349Suche in Google Scholar PubMed
[27] Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2004;25:1157–74.10.1002/jcc.20035Suche in Google Scholar PubMed
[28] Izaguirre JA, Catarello DP, Wozniak JM, Skeel RD. Langevin stabilization of molecular dynamics. J Chem Phys. 2001;114:2090–8.10.1063/1.1332996Suche in Google Scholar
[29] Ryckaert J-P, Ciccotti G, Berendsen HJ. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys. 1977;23:327–41.10.1016/0021-9991(77)90098-5Suche in Google Scholar
[30] Chang Y, Fang WB, Lin SN, Moody DE. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: A reconciliation. Basic Clin Pharmacol Toxicol. 2011;108:55–62.10.1111/j.1742-7843.2010.00628.xSuche in Google Scholar PubMed PubMed Central
[31] Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther. 2007;321:389–99.10.1124/jpet.106.117580Suche in Google Scholar PubMed
[32] Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology. 2008;108:363–74.10.1097/ALN.0b013e3181642938Suche in Google Scholar PubMed
[33] Olubiyi OO, Olagunju MO, Obisesan AO. Computational analysis of physicochemical factors driving CYP2D6 ligand interaction. Curr Comput Aided Drug Des. 2017;13:39–47.10.2174/1573409912666160909092600Suche in Google Scholar PubMed
[34] Hendrychova T, Anzenbacherova E, Hudecek J, Skopalik J, Lange R, Hildebrandt P, et al. Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations. Biochim Biophys Acta. 2011;1814:58–68.10.1016/j.bbapap.2010.07.017Suche in Google Scholar PubMed
[35] Sano E, Li W, Yuki H, Liu X, Furihata T, Kobayashi K, et al. Mechanism of the decrease in catalytic activity of human cytochrome P450 2C9 polymorphic variants investigated by computational analysis. J Comput Chem. 2010;31:2746–58.10.1002/jcc.21568Suche in Google Scholar PubMed
© 2019 Walter de Gruyter GmbH, Berlin/Boston
Artikel in diesem Heft
- Micro-Raman spectroscopy in medicine
- Computational prediction of toxicity of small organic molecules: state-of-the-art
- Phthalocyanines core-modified by P and S and their complexes with fullerene C60: DFT study
- From beams to glass: determining compositions to study provenance and production techniques
- Computational methods for NMR and MS for structure elucidation I: software for basic NMR
- Conformations and interactions comparison between R- and S-methadone in wild type CYP2B6, 2D6 and 3A4
- Applications of magnetic resonance imaging in chemical engineering
- Combined approach of homology modeling, molecular dynamics, and docking: computer-aided drug discovery
Artikel in diesem Heft
- Micro-Raman spectroscopy in medicine
- Computational prediction of toxicity of small organic molecules: state-of-the-art
- Phthalocyanines core-modified by P and S and their complexes with fullerene C60: DFT study
- From beams to glass: determining compositions to study provenance and production techniques
- Computational methods for NMR and MS for structure elucidation I: software for basic NMR
- Conformations and interactions comparison between R- and S-methadone in wild type CYP2B6, 2D6 and 3A4
- Applications of magnetic resonance imaging in chemical engineering
- Combined approach of homology modeling, molecular dynamics, and docking: computer-aided drug discovery
